The DOI matches its Crossref record; the references it cites are not checked yet.
EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency
Open accessAbstract
Molecular genetic testing for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is offered worldwide and is of importance for differential diagnosis, carrier detection and adequate genetic counseling, particularly for family planning. In 2008 the European Molecular Genetics Quality Network (EMQN) for the first time offered a European-wide external quality assessment scheme for CAH (due to 21-OH deficiency). The interest was great and over the last years at about 60 laboratories from Europe, USA and Australia regularly participated in that scheme. These best practice guidelines were drafted on the basis of the extensive knowledge and experience got from those annually organized CAH-schemes. In order to obtain the widest possible consultation with practicing laboratories the draft was therefore circulated twice by EMQN to all laboratories participating in the EQA-scheme for CAH genotyping and was updated by that input. The present guidelines address quality requirements for diagnostic molecular genetic laboratories, as well as criteria for CYP21A 2 genotyping (including carrier-testing and prenatal diagnosis). A key aspect of that article is the use of appropriate methodologies (e.g., sequencing methods, MLPA (multiplex ligation dependent probe amplification), mutation specific assays) and respective limitations and analytical accuracy. Moreover, these guidelines focus on classification of variants, and the interpretation and standardization of the reporting of CYP21A2 genotyping results. In addition, the article provides a comprehensive list of common as well as so far unreported CYP21A2-variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, our findings support the concept that standard NGS-based methodologies are not yet suitable for the genetic testing of RCCX module genes within the homologous window, not only for CYP21A2 but also for TNXB exons 32–44 [14,31,41].”
From Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decades, diagnostic approaches have evolved from locus-specific assays, such as allele-specific polymerase chain reaction, to the combined use of Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA), which together constituted the historical gold-standard approach strategy capable of identifying pathogenic variants, deletions and chimeric alleles.”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Introduced in the early 2000s, MLPA represented a major advance in the molecular diagnosis of CAH providing a rapid, sensitive, and non-radioactive method to detect copy-number variation (CNV) within the CYP21A2 locus.”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than three decades, Sanger sequencing has been regarded as the gold standard for CYP21A2 analysis and remains the reference method in diagnostic and research laboratories worldwide (22, 47, 53).”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Even in the era of high-throughput sequencing, Sanger-based workflows continue to be recommended by international guidelines such as the EMQN for confirmatory testing and variant verification (53).”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 229 · Cited by 110
Research works printed but not linked: 9
- Tardy V. Management of pregnancies at risk of 21-hydroxylase or 11-hydroxylase deficiency using fetal sex determination in maternal serum proposed in France since 2002: how to limit prenatal exposure to dexamethasone. Horm Res. 2009;70(Suppl 3):348.
- Tardy V. Gene symbol: CYP21A2. Disease: steroid 21-hydroxylase deficiency. Hum Genet. 2006;119/3:363.
- Tardy VT, Morel Y. Gene symbol: CYP21A2. Hum Genet. 2007;121/2:293–4.
- Speiser PW, New MI, White PC. Molecular genetic analysis of nonclassic steriod 21-hydroxylase deficiency associated with HLA-B14,DR1. N Engl J Med. 1988;319/1:19–23. · DOI · Paper page
- Bleicken C, Loidi L, Dhir V, Parajes S, Quinteiro C, Dominguez F, et al. Functional characterization of three CYP21A2 sequence variants (p.A265V, p.W302S, p.D322G) employing a yeast co-expression system. Hum Mutat. 2009;30(Feb):E443–50. https://doi.org/10.1002/humu.20926. · DOI · Paper page
- Baradaran-Heravi A, Vakili R, Robins T, Carlsson J, Ghaemi N, Aʼrabi A, et al. Three novel CYP21A2 mutations and their protein modelling in patients with classical 21-hydroxylase deficiency from northeastern Iran. Clin Endocrinol (Oxf). 2007;67/3:335–41. · DOI
- Baumgartner-Parzer SM, Schulze E, Waldhäusl W, Pauschenwein S, Rondot S, Nowotny P, et al. Mutational spectrum of the steroid 21-hyxdroxylase gene in Austria: identification of a novel missense mutation. J Clin Endocrinol Metab. 2001;86/10:4771–5. · DOI · Paper page
- Ordoñez-Sánchez ML, Ramírez-Jiménez S, López-Gutierrez AU, Riba L, Gamboa-Cardiel S, Cerrillo-Hinojosa M, et al. Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: identification of possible new mutations and high prevalence of apparent germ-line mutations. Hum Genet. 1998;102/2:170–7.
- Wedell A, Luthman H. Steroid 21-hydroxylase (P450c21): a new allele and spread of mutations through the pseudogene. Hum Genet. 1993;91/3:236–40.
Metadata
- Authors
- Baumgartner-Parzer, S., Witsch-Baumgartner, M., & Hoeppner, W.
- Affiliations
- Medical University of Vienna (AT)
- Bioglobe (Germany) (DE)
- Corresponding author
- Baumgartner-Parzer, Sabina
- Venue
- European Journal of Human Genetics
- Published
- 2020-07-02
- Volume
- 28
- Issue
- 10
- Pages
- 1341-1367
- ISSN
- 1018-4813 (ISSN-L)
- 1476-5438
- PMC
- PMC7609334
- OpenAlex
- W3039819996
- Cited by
- 110
- References
- 229
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 20 · 2023: 18 · 2022: 12 · 2021: 19
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European Journal of Human Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, molecular genetic testing, external quality assessment, variant interpretation, genetic counseling, carrier screening, prenatal diagnosis, multiplex ligation-dependent probe amplification, variant reporting
- MeSH terms
- Adrenal Hyperplasia, Congenital, Consensus Statements as Topic, Europe, Genetic Testing, Humans, Quality Assurance, Health Care, Databases, Factual, Practice Guidelines as Topic, Cytochrome P-450 CYP1A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. https://app.cochat.ai/papers/10.1038/s41431-020-0653-5
- The paper
- Baumgartner-Parzer, S., Witsch-Baumgartner, M., & Hoeppner, W. (2020). EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. European Journal of Human Genetics. https://doi.org/10.1038/s41431-020-0653-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.